CA2257852C - Transgenic non-human mammals with progressive neurologic disease - Google Patents

Transgenic non-human mammals with progressive neurologic disease Download PDF

Info

Publication number: CA2257852C
Authority: CA; Canada
Prior art keywords: app; mouse; transgenic; mice; mutation
Prior art date: 1996-06-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA2257852A

Other languages

English (en)

French (fr)

Other versions

CA2257852A1 (en

Inventor

Karen Hsiao

David R. Borchelt

Sangram S. Sisodia

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Johns Hopkins University

University of Minnesota

Original Assignee

Johns Hopkins University

University of Minnesota

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-17

Filing date

1997-06-17

Publication date

2010-02-23

1997-06-17 Application filed by Johns Hopkins University, University of Minnesota filed Critical Johns Hopkins University

1997-12-24 Publication of CA2257852A1 publication Critical patent/CA2257852A1/en

2010-02-23 Application granted granted Critical

2010-02-23 Publication of CA2257852C publication Critical patent/CA2257852C/en

2017-06-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000009261 transgenic effect Effects 0.000 title abstract description 105
208000012902 Nervous system disease Diseases 0.000 title description 50
230000000750 progressive effect Effects 0.000 title description 42
101710137189 Amyloid-beta A4 protein Proteins 0.000 claims abstract description 250
101710151993 Amyloid-beta precursor protein Proteins 0.000 claims abstract description 250
102100022704 Amyloid-beta precursor protein Human genes 0.000 claims abstract description 246
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical group C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims abstract description 244
238000011830 transgenic mouse model Methods 0.000 claims abstract description 183
210000004556 brain Anatomy 0.000 claims abstract description 124
108091000054 Prion Proteins 0.000 claims abstract description 89
108700019146 Transgenes Proteins 0.000 claims description 153
230000035772 mutation Effects 0.000 claims description 120
208000024827 Alzheimer disease Diseases 0.000 claims description 105
208000037259 Amyloid Plaque Diseases 0.000 claims description 58
238000000034 method Methods 0.000 claims description 45
238000010186 staining Methods 0.000 claims description 43
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 42
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 42
239000004474 valine Substances 0.000 claims description 42
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 claims description 32
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 21
238000012216 screening Methods 0.000 claims description 20
239000003795 chemical substances by application Substances 0.000 claims description 18
150000001413 amino acids Chemical class 0.000 claims description 16
230000008569 process Effects 0.000 claims description 10
208000024891 symptom Diseases 0.000 claims description 6
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 3
241001465754 Metazoa Species 0.000 abstract description 163
241000699670 Mus sp. Species 0.000 abstract description 161
241000699660 Mus musculus Species 0.000 abstract description 129
230000014509 gene expression Effects 0.000 abstract description 98
241000699666 Mus <mouse, genus> Species 0.000 abstract description 74
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 45
206010018341 Gliosis Diseases 0.000 abstract description 43
230000007387 gliosis Effects 0.000 abstract description 39
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 27
239000008103 glucose Substances 0.000 abstract description 27
241000699800 Cricetinae Species 0.000 abstract description 26
230000034994 death Effects 0.000 abstract description 19
231100000517 death Toxicity 0.000 abstract description 19
239000013601 cosmid vector Substances 0.000 abstract description 16
230000003292 diminished effect Effects 0.000 abstract description 16
230000002490 cerebral effect Effects 0.000 abstract description 14
206010010904 Convulsion Diseases 0.000 abstract description 11
238000013019 agitation Methods 0.000 abstract description 9
208000015114 central nervous system disease Diseases 0.000 abstract description 9
230000003941 amyloidogenesis Effects 0.000 abstract description 8
230000001419 dependent effect Effects 0.000 abstract description 8
210000004602 germ cell Anatomy 0.000 abstract description 7
230000001133 acceleration Effects 0.000 abstract description 2
230000001717 pathogenic effect Effects 0.000 abstract 1
210000001082 somatic cell Anatomy 0.000 abstract 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 145
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 145
229960001230 asparagine Drugs 0.000 description 145
235000009582 asparagine Nutrition 0.000 description 145
235000004279 alanine Nutrition 0.000 description 107
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 106
108090000623 proteins and genes Proteins 0.000 description 77
108020004414 DNA Proteins 0.000 description 64
238000012360 testing method Methods 0.000 description 62
210000004027 cell Anatomy 0.000 description 52
102000029797 Prion Human genes 0.000 description 49
230000003542 behavioural effect Effects 0.000 description 38
210000001320 hippocampus Anatomy 0.000 description 37
238000003752 polymerase chain reaction Methods 0.000 description 36
230000005856 abnormality Effects 0.000 description 34
229930182817 methionine Natural products 0.000 description 33
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 32
201000010099 disease Diseases 0.000 description 29
239000012634 fragment Substances 0.000 description 29
238000011771 FVB mouse Methods 0.000 description 28
230000004927 fusion Effects 0.000 description 28
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 28
102000004169 proteins and genes Human genes 0.000 description 28
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 27
229930195712 glutamate Natural products 0.000 description 27
230000001771 impaired effect Effects 0.000 description 26
108091026890 Coding region Proteins 0.000 description 25
210000005013 brain tissue Anatomy 0.000 description 25
238000004458 analytical method Methods 0.000 description 24
229960000310 isoleucine Drugs 0.000 description 23
235000018102 proteins Nutrition 0.000 description 23
101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 22
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 22
210000003710 cerebral cortex Anatomy 0.000 description 22
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 22
230000000694 effects Effects 0.000 description 21
230000001575 pathological effect Effects 0.000 description 21
210000001519 tissue Anatomy 0.000 description 20
239000000047 product Substances 0.000 description 19
239000000523 sample Substances 0.000 description 19
108020004707 nucleic acids Proteins 0.000 description 18
102000039446 nucleic acids Human genes 0.000 description 18
150000007523 nucleic acids Chemical class 0.000 description 18
210000004727 amygdala Anatomy 0.000 description 17
108090000765 processed proteins & peptides Proteins 0.000 description 17
230000001747 exhibiting effect Effects 0.000 description 16
210000002569 neuron Anatomy 0.000 description 16
101000823042 Mus musculus Amyloid-beta precursor protein Proteins 0.000 description 15
108700026244 Open Reading Frames Proteins 0.000 description 15
102000046783 human APP Human genes 0.000 description 15
230000002103 transcriptional effect Effects 0.000 description 15
230000014621 translational initiation Effects 0.000 description 15
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 14
108020004705 Codon Proteins 0.000 description 14
230000002159 abnormal effect Effects 0.000 description 14
239000002299 complementary DNA Substances 0.000 description 14
230000006735 deficit Effects 0.000 description 14
235000019253 formic acid Nutrition 0.000 description 14
102000004196 processed proteins & peptides Human genes 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
238000010276 construction Methods 0.000 description 13
208000035475 disorder Diseases 0.000 description 13
210000001161 mammalian embryo Anatomy 0.000 description 13
102000053171 Glial Fibrillary Acidic Human genes 0.000 description 12
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 12
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 12
238000011161 development Methods 0.000 description 12
230000018109 developmental process Effects 0.000 description 12
230000001969 hypertrophic effect Effects 0.000 description 12
239000000463 material Substances 0.000 description 12
238000012545 processing Methods 0.000 description 12
238000011144 upstream manufacturing Methods 0.000 description 12
101150031224 app gene Proteins 0.000 description 11
230000027455 binding Effects 0.000 description 11
210000001638 cerebellum Anatomy 0.000 description 11
241000894007 species Species 0.000 description 11
108700005000 Glial Fibrillary Acidic Proteins 0.000 description 10
241000282412 Homo Species 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
235000013601 eggs Nutrition 0.000 description 10
239000003623 enhancer Substances 0.000 description 10
230000004190 glucose uptake Effects 0.000 description 10
238000003119 immunoblot Methods 0.000 description 10
238000011534 incubation Methods 0.000 description 10
230000000977 initiatory effect Effects 0.000 description 10
230000003188 neurobehavioral effect Effects 0.000 description 10
230000007170 pathology Effects 0.000 description 10
238000011282 treatment Methods 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
108700028146 Genetic Enhancer Elements Proteins 0.000 description 9
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 9
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 9
108091036066 Three prime untranslated region Proteins 0.000 description 9
230000006399 behavior Effects 0.000 description 9
239000013598 vector Substances 0.000 description 9
102100034323 Disintegrin and metalloproteinase domain-containing protein 2 Human genes 0.000 description 8
101000780288 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 2 Proteins 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000000284 extract Substances 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
230000002981 neuropathic effect Effects 0.000 description 8
230000002028 premature Effects 0.000 description 8
238000011160 research Methods 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 7
230000003140 astrocytic effect Effects 0.000 description 7
210000000478 neocortex Anatomy 0.000 description 7
210000002682 neurofibrillary tangle Anatomy 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
230000001105 regulatory effect Effects 0.000 description 7
230000004044 response Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
229910052709 silver Inorganic materials 0.000 description 7
239000004332 silver Substances 0.000 description 7
238000012549 training Methods 0.000 description 7
VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 6
206010012289 Dementia Diseases 0.000 description 6
239000004471 Glycine Substances 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 6
102000054727 Serum Amyloid A Human genes 0.000 description 6
108700028909 Serum Amyloid A Proteins 0.000 description 6
PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 6
210000001130 astrocyte Anatomy 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
238000012986 modification Methods 0.000 description 6
208000015122 neurodegenerative disease Diseases 0.000 description 6
208000011580 syndromic disease Diseases 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
241000283707 Capra Species 0.000 description 5
241000288906 Primates Species 0.000 description 5
241000283984 Rodentia Species 0.000 description 5
229940024606 amino acid Drugs 0.000 description 5
238000010171 animal model Methods 0.000 description 5
238000003776 cleavage reaction Methods 0.000 description 5
210000004748 cultured cell Anatomy 0.000 description 5
230000007423 decrease Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
210000002257 embryonic structure Anatomy 0.000 description 5
230000006870 function Effects 0.000 description 5
238000012744 immunostaining Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
230000003137 locomotive effect Effects 0.000 description 5
230000004048 modification Effects 0.000 description 5
230000001537 neural effect Effects 0.000 description 5
230000007171 neuropathology Effects 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000007017 scission Effects 0.000 description 5
230000002123 temporal effect Effects 0.000 description 5
206010000117 Abnormal behaviour Diseases 0.000 description 4
102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
102000009091 Amyloidogenic Proteins Human genes 0.000 description 4
108010048112 Amyloidogenic Proteins Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
238000012347 Morris Water Maze Methods 0.000 description 4
241001529936 Murinae Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
108700008625 Reporter Genes Proteins 0.000 description 4
206010039966 Senile dementia Diseases 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
230000003942 amyloidogenic effect Effects 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
230000001054 cortical effect Effects 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000004064 dysfunction Effects 0.000 description 4
210000001353 entorhinal cortex Anatomy 0.000 description 4
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
210000003734 kidney Anatomy 0.000 description 4
230000002197 limbic effect Effects 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
210000000278 spinal cord Anatomy 0.000 description 4
210000000952 spleen Anatomy 0.000 description 4
230000009182 swimming Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
238000012353 t test Methods 0.000 description 4
210000001550 testis Anatomy 0.000 description 4
MYGCFWRBKKQKCG-GBWOLBBFSA-N (z,2r,3s,4r)-hex-5-ene-1,2,3,4,6-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)\C=C/O MYGCFWRBKKQKCG-GBWOLBBFSA-N 0.000 description 3
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
239000005695 Ammonium acetate Substances 0.000 description 3
206010003445 Ascites Diseases 0.000 description 3
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 3
101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 3
206010011906 Death Diseases 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
208000026139 Memory disease Diseases 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
102000007999 Nuclear Proteins Human genes 0.000 description 3
108010089610 Nuclear Proteins Proteins 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
235000019257 ammonium acetate Nutrition 0.000 description 3
229940043376 ammonium acetate Drugs 0.000 description 3
208000037875 astrocytosis Diseases 0.000 description 3
230000007341 astrogliosis Effects 0.000 description 3
210000004227 basal ganglia Anatomy 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000000133 brain stem Anatomy 0.000 description 3
210000003591 cerebellar nuclei Anatomy 0.000 description 3
210000004720 cerebrum Anatomy 0.000 description 3
238000010367 cloning Methods 0.000 description 3
208000010877 cognitive disease Diseases 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
230000008021 deposition Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
210000001671 embryonic stem cell Anatomy 0.000 description 3
230000021824 exploration behavior Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000002518 glial effect Effects 0.000 description 3
238000007654 immersion Methods 0.000 description 3
230000006872 improvement Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000000203 mixture Substances 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
210000002241 neurite Anatomy 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
230000002018 overexpression Effects 0.000 description 3
239000012188 paraffin wax Substances 0.000 description 3
230000001936 parietal effect Effects 0.000 description 3
231100000915 pathological change Toxicity 0.000 description 3
230000036285 pathological change Effects 0.000 description 3
239000013641 positive control Substances 0.000 description 3
230000036544 posture Effects 0.000 description 3
239000002243 precursor Substances 0.000 description 3
210000004129 prosencephalon Anatomy 0.000 description 3
210000002763 pyramidal cell Anatomy 0.000 description 3
210000004189 reticular formation Anatomy 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
210000000813 small intestine Anatomy 0.000 description 3
210000001587 telencephalon Anatomy 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
230000014616 translation Effects 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
102100040038 Amyloid beta precursor like protein 2 Human genes 0.000 description 2
206010002942 Apathy Diseases 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
208000028698 Cognitive impairment Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
108700024394 Exon Proteins 0.000 description 2
206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 2
101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
101000890401 Homo sapiens Amyloid beta precursor like protein 2 Proteins 0.000 description 2
206010021034 Hypometabolism Diseases 0.000 description 2
GAAKALASJNGQKD-UHFFFAOYSA-N LY-165163 Chemical compound C1=CC(N)=CC=C1CCN1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 GAAKALASJNGQKD-UHFFFAOYSA-N 0.000 description 2
108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
208000008457 Neurologic Manifestations Diseases 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
102100022033 Presenilin-1 Human genes 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
108010019674 Proto-Oncogene Proteins c-sis Proteins 0.000 description 2
238000010240 RT-PCR analysis Methods 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
206010044565 Tremor Diseases 0.000 description 2
108091023045 Untranslated Region Proteins 0.000 description 2
ZHAFUINZIZIXFC-UHFFFAOYSA-N [9-(dimethylamino)-10-methylbenzo[a]phenoxazin-5-ylidene]azanium;chloride Chemical compound [Cl-].O1C2=CC(=[NH2+])C3=CC=CC=C3C2=NC2=C1C=C(N(C)C)C(C)=C2 ZHAFUINZIZIXFC-UHFFFAOYSA-N 0.000 description 2
QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
238000000540 analysis of variance Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000006736 behavioral deficit Effects 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000004891 communication Methods 0.000 description 2
210000000877 corpus callosum Anatomy 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
229940009976 deoxycholate Drugs 0.000 description 2
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000008451 emotion Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
208000015756 familial Alzheimer disease Diseases 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000005755 formation reaction Methods 0.000 description 2
230000008014 freezing Effects 0.000 description 2
238000007710 freezing Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
102000034356 gene-regulatory proteins Human genes 0.000 description 2
108091006104 gene-regulatory proteins Proteins 0.000 description 2
210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
210000005154 hemibrain Anatomy 0.000 description 2
230000002962 histologic effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
230000010354 integration Effects 0.000 description 2
QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
238000000329 molecular dynamics simulation Methods 0.000 description 2
108700024542 myc Genes Proteins 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
230000007121 neuropathological change Effects 0.000 description 2
210000000287 oocyte Anatomy 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000010076 replication Effects 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000001953 sensory effect Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
210000003699 striated muscle Anatomy 0.000 description 2
108020001568 subdomains Proteins 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000033912 thigmotaxis Effects 0.000 description 2
-1 thioflavin S Chemical compound 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000001720 vestibular Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
108010060159 Apolipoprotein E4 Proteins 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
101100539485 Caenorhabditis elegans unc-86 gene Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010947 Coordination abnormal Diseases 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
102100031334 Elongation factor 2 Human genes 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
101710191797 Gamma-enolase Proteins 0.000 description 1
102100028652 Gamma-enolase Human genes 0.000 description 1
108700023863 Gene Components Proteins 0.000 description 1
206010019196 Head injury Diseases 0.000 description 1
101100268553 Homo sapiens APP gene Proteins 0.000 description 1
101000573901 Homo sapiens Major prion protein Proteins 0.000 description 1
101000659324 Homo sapiens Twinfilin-1 Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
244000027321 Lychnis chalcedonica Species 0.000 description 1
XBZOQGHZGQLEQO-IUCAKERBSA-N Lys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN XBZOQGHZGQLEQO-IUCAKERBSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
208000027382 Mental deterioration Diseases 0.000 description 1
206010027374 Mental impairment Diseases 0.000 description 1
101001090203 Mus musculus Major prion protein Proteins 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
101150054854 POU1F1 gene Proteins 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
108010077519 Peptide Elongation Factor 2 Proteins 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
108010036933 Presenilin-1 Proteins 0.000 description 1
102000012419 Presenilin-2 Human genes 0.000 description 1
108010036908 Presenilin-2 Proteins 0.000 description 1
208000032561 Rare neurodegenerative disease Diseases 0.000 description 1
101001058233 Rattus norvegicus Gamma-enolase Proteins 0.000 description 1
108700005075 Regulator Genes Proteins 0.000 description 1
206010040021 Sensory abnormalities Diseases 0.000 description 1
206010040030 Sensory loss Diseases 0.000 description 1
108010052164 Sodium Channels Proteins 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
150000001294 alanine derivatives Chemical class 0.000 description 1
230000004075 alteration Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
230000037429 base substitution Effects 0.000 description 1
208000013404 behavioral symptom Diseases 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
230000005978 brain dysfunction Effects 0.000 description 1
230000003925 brain function Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
238000000339 bright-field microscopy Methods 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000007585 cortical function Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
210000002451 diencephalon Anatomy 0.000 description 1
AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
230000005584 early death Effects 0.000 description 1
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
230000007831 electrophysiology Effects 0.000 description 1
238000002001 electrophysiology Methods 0.000 description 1
230000001158 estrous effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000835 fiber Substances 0.000 description 1
230000035557 fibrillogenesis Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
210000005153 frontal cortex Anatomy 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000011521 glass Substances 0.000 description 1
108060003196 globin Proteins 0.000 description 1
239000003862 glucocorticoid Substances 0.000 description 1
230000004153 glucose metabolism Effects 0.000 description 1
208000035474 group of disease Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
210000004295 hippocampal neuron Anatomy 0.000 description 1
230000036732 histological change Effects 0.000 description 1
238000007489 histopathology method Methods 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
230000005571 horizontal transmission Effects 0.000 description 1
102000044945 human APLP2 Human genes 0.000 description 1
102000050945 human TWF1 Human genes 0.000 description 1
238000011577 humanized mouse model Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000016290 incoordination Diseases 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000021001 locomotory behavior Effects 0.000 description 1
238000013507 mapping Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
230000002025 microglial effect Effects 0.000 description 1
230000007388 microgliosis Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
230000009251 neurologic dysfunction Effects 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
238000010606 normalization Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
229940012982 picot Drugs 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
235000008476 powdered milk Nutrition 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000007639 printing Methods 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
210000001176 projection neuron Anatomy 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
VBUBYMVULIMEHR-UHFFFAOYSA-N propa-1,2-diene;prop-1-yne Chemical compound CC#C.C=C=C VBUBYMVULIMEHR-UHFFFAOYSA-N 0.000 description 1
230000005892 protein maturation Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
239000001044 red dye Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000001202 rhombencephalon Anatomy 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
208000008864 scrapie Diseases 0.000 description 1
230000009758 senescence Effects 0.000 description 1
102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 1
108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 1
230000003584 silencer Effects 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000024188 startle response Effects 0.000 description 1
230000007470 synaptic degeneration Effects 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012301 transgenic model Methods 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
230000001755 vocal effect Effects 0.000 description 1
239000008096 xylene Substances 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
- A01K2267/0343—Animal model for prion disease
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Environmental Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Wood Science & Technology (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Biodiversity & Conservation Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Animal Husbandry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Rheumatology (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Urology & Nephrology (AREA)
Pathology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

CA2257852A 1996-06-17 1997-06-17 Transgenic non-human mammals with progressive neurologic disease Expired - Lifetime CA2257852C (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/664,872 US5877399A (en)	1994-01-27	1996-06-17	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US08/664,872		1996-06-17
PCT/US1997/010052 WO1997048792A1 (en)	1996-06-17	1997-06-17	Transgenic non-human mammals with progressive neurologic disease

Publications (2)

Publication Number	Publication Date
CA2257852A1 CA2257852A1 (en)	1997-12-24
CA2257852C true CA2257852C (en)	2010-02-23

Family

ID=24667796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2257852A Expired - Lifetime CA2257852C (en)	1996-06-17	1997-06-17	Transgenic non-human mammals with progressive neurologic disease

Country Status (6)

Country	Link
US (3)	US5877399A (ja)
EP (1)	EP0904349A4 (ja)
JP (1)	JP2000513929A (ja)
AU (1)	AU3481897A (ja)
CA (1)	CA2257852C (ja)
WO (1)	WO1997048792A1 (ja)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH09511388A (ja) *	1994-01-27	1997-11-18	リージェンツオブザユニバーシティーオブミネソタ	進行性神経疾患を持つヒト以外のトランスジェニック哺乳類
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
US6717031B2 (en)	1995-06-07	2004-04-06	Kate Dora Games	Method for selecting a transgenic mouse model of alzheimer's disease
US20010016951A1 (en) *	1996-07-24	2001-08-23	Bernd Sommer	Transgenic animal model for alzheimer disease
EP0994728B1 (en)	1997-04-09	2008-07-30	Intellect Neurosciences, Inc.	Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof
US6284944B1 (en) *	1997-08-29	2001-09-04	Cephalon, Inc,	Gene-targeted non-human mammal with a human fad presenilin mutation and generational offspring
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US6743427B1 (en)	1997-12-02	2004-06-01	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7179892B2 (en) *	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
US6750324B1 (en)	1997-12-02	2004-06-15	Neuralab Limited	Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en)	1997-12-02	2004-03-23	Neuralab Limited	Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US20080050367A1 (en) *	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) *	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
JP4290329B2 (ja) *	1998-01-08	2009-07-01	第一三共株式会社	遺伝子変異動物
ATE302267T1 (de) *	1998-01-08	2005-09-15	Aventis Pharma Inc	Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
US6664443B1 (en)	1998-05-01	2003-12-16	Mayo Foundation For Medical Education And Research	Pathogenic Tau mutations in transgenic mice
JP2002513551A (ja)	1998-05-01	2002-05-14	マヨファウンデーションフォーメディカルエデュケーションアンドリサーチ	病原性タウ突然変異
US20030147882A1 (en) *	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
US6518011B1 (en) *	1999-01-13	2003-02-11	Bristol-Myers Squibb Company	Method for screening compounds to identify beta-amyloid production modulators
JP2001017028A (ja) *	1999-05-06	2001-01-23	Mitsubishi Chemicals Corp	アポｅヒト化哺乳動物
US6670195B1 (en)	1999-05-26	2003-12-30	New York University	Mutant genes in Familial British Dementia and Familial Danish Dementia
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en) *	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
US6610905B1 (en)	1999-07-21	2003-08-26	Schering Corporation	Transgenic mouse model for Kaposi's sarcoma
US7273964B1 (en)	1999-08-06	2007-09-25	Scuola Internazionale Superiore Di Studi Avanzati	Non-human transgenic animals for the study of neurodegenerative syndromes
EP1265849B1 (en)	2000-03-23	2006-10-25	Elan Pharmaceuticals, Inc.	Compounds and methods to treat alzheimer's disease
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
IL151828A0 (en) *	2000-04-03	2003-04-10	Bristol Myers Squibb Pharma Co	Proteins having gamma-secretase activity and methods for isolating the same and methods detecting said activity
ATE499832T1 (de)	2000-06-20	2011-03-15	Univ Toronto	Transgenes tiermodel für neurodegenerative krankheiten
US7371920B2 (en) *	2000-06-20	2008-05-13	The Governing Council Of The University Of Toronto	Transgenic mouse model of neurodegenerative disorders
EP1299349B1 (en) *	2000-06-30	2005-08-24	Elan Pharmaceuticals, Inc.	Compounds to treat alzheimer's disease
EP1666452A2 (en)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
EP1326997A4 (en) *	2000-09-25	2006-01-11	Univ	MODEL FOR NEURODEGENERATIVE DISEASES WITH AMYLOIDAC CUMULATION
TWI255272B (en) *	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
WO2002067167A1 (fr) *	2001-02-22	2002-08-29	Sony Corporation	Systeme de fourniture et d'acquisition de contenus
BR0210122A (pt) *	2001-06-01	2004-06-15	Elan Pharm Inc	Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
EP1395251A2 (en)	2001-06-13	2004-03-10	Elan Pharmaceuticals, Inc.	Aminediols as agents for the treatment of alzheimer's disease
MXPA04000140A (es) *	2001-06-27	2004-06-03	Elan Pharm Inc	Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
US20070213407A1 (en) *	2001-06-29	2007-09-13	Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc	Compounds to treat Alzheimer's disease
WO2003002754A2 (en) *	2001-06-29	2003-01-09	Mayo Foundation For Medical Education & Research	Bri constructs and methods of using
WO2003006013A1 (en) *	2001-07-10	2003-01-23	Elan Pharmaceuticals, Inc.	Diaminediols for the treatment of alzheimer's disease
BR0211121A (pt) *	2001-07-10	2004-10-26	Elan Pharm Inc	Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
US7297553B2 (en) *	2002-05-28	2007-11-20	Nanosphere, Inc.	Method for attachment of silylated molecules to glass surfaces
WO2003029169A2 (en)	2001-10-04	2003-04-10	Elan Pharmaceuticals, Inc.	Hydroxypropylamines
OA12846A (en) *	2001-11-08	2006-09-15	Elan Pharm Inc	N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives.
JP4343695B2 (ja) *	2001-12-20	2009-10-14	ザリージェンツオブザユニバーシティオブカリフォルニア	アルツハイマー病のトリプル・トランスジェニックマウス・モデル
JP4508645B2 (ja)	2002-01-04	2010-07-21	ザロックフェラーユニバーシティー	アミロイド−βペプチド関連疾患の予防および治療用の組成物および方法
US20040016008A1 (en) *	2002-01-07	2004-01-22	Brimijoin William Stephen	Hybrid transgenic mouse with accelerated onsent of Alzheimer type amyloid plaques in brain
EP1478736A4 (en) *	2002-02-27	2007-01-10	Pharmacia & Upjohn Co Llc	PRODUCTION OF AMYLOID BETA PEPTIDES FROM IMR-32 CELLS AT HIGH LEVEL
MY139983A (en) *	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
US7262208B2 (en) *	2002-04-30	2007-08-28	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of Alzheimer's disease
UY27967A1 (es) *	2002-09-10	2004-05-31	Pfizer	Acetil 2-hindroxi-1,3-diaminoalcanos
US7351738B2 (en) *	2002-11-27	2008-04-01	Elan Pharmaceuticals, Inc.	Substituted ureas and carbamates
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
RU2390350C2 (ru) *	2003-02-01	2010-05-27	Ньюралаб Лимитед	Активная иммунизация для создания антител к растворимому а-бета
US7341847B2 (en) *	2003-04-02	2008-03-11	Agency For Science, Technology And Research	Promoter construct for gene expression in neuronal cells
EP1615915A1 (en) *	2003-04-21	2006-01-18	Elan Pharmaceuticals, Inc.	Phenacyl 2-hydroxy-3-diaminoalkanes
CA2523232A1 (en) *	2003-04-21	2004-11-04	Elan Pharmaceuticals, Inc.	(hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
CA2553973A1 (en) *	2004-01-21	2005-08-04	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using aspartyl-protease inihibitors
WO2005087714A2 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
JP2007528402A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
CA2558034A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
WO2005087215A1 (en)	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
SE0400707D0 (sv)	2004-03-22	2004-03-22	Bioarctic Neuroscience Ab	Transgenic animal model
US7544855B2 (en) *	2004-04-23	2009-06-09	Buck Institute	Transgenic mouse whose genome comprises an APP having a mutation at amino acid 664
EP1750719A2 (en) *	2004-05-19	2007-02-14	Boehringer Ingelheim International GmbH	Treatment of diseases associated with altered level of amyloid beta peptides
JP2008505929A (ja) *	2004-07-09	2008-02-28	エランファーマシューティカルズ，インコーポレイテッド	オキシム誘導体ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
EP1773756A2 (en) *	2004-07-09	2007-04-18	Elan Pharmaceuticals, Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
CA2488113A1 (en) *	2004-11-18	2006-05-18	Jean Michel Heard	A non-human animal alzheimer's disease model and uses thereof
US8426429B2 (en) *	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US20060074098A1 (en) *	2004-08-27	2006-04-06	Roy Hom	Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors
CN101072591A (zh) *	2004-11-05	2007-11-14	惠氏公司	用于筛选阿尔茨海默病治疗剂的pet和磁共振
ES2434732T3 (es) *	2004-12-15	2013-12-17	Janssen Alzheimer Immunotherapy	Anticuerpos para beta-amiloide humanizados para su uso en mejorar la cognición
WO2006066049A2 (en) *	2004-12-15	2006-06-22	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
EP1838349A1 (en) *	2004-12-15	2007-10-03	Neuralab, Ltd.	Amyloid beta antibodies for use in improving cognition
WO2006069697A1 (en) *	2004-12-30	2006-07-06	F. Hoffmann-La Roche Ag	Colorimetrically assessing peptide characteristics
AU2006214179A1 (en)	2005-02-17	2006-08-24	Biogen Idec Ma Inc.	Treating neurological disorders
US20060272038A1 (en) *	2005-05-27	2006-11-30	Michael De Vivo	Transgenic Alzheimer's mouse model vectors and uses thereof
EP1746092A1 (en)	2005-07-22	2007-01-24	Exonhit Therapeutics SA	Compounds and methods for treatment of amyloid-B-peptide related disorders
EP1913017A1 (en) *	2005-08-03	2008-04-23	Boehringer Ingelheim International GmbH	Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii
WO2007017511A2 (de) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Verbindungen zur behandlung der alzheimer erkrankung
WO2007017510A2 (de) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Isophthalsäurediamide zur behandlung der alzheimer erkrankung
CA2618013A1 (en) *	2005-08-11	2007-02-15	Boehringer Ingelheim International Gmbh	Beta-secretase inhibitors for use in the treatment of alzheimer's disease
JP2009504612A (ja) *	2005-08-11	2009-02-05	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	アルツハイマー病の治療用化合物
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
CA2624904A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
PT1976877E (pt)	2005-11-30	2014-04-29	Abbvie Inc	Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
ES2524984T3 (es)	2005-11-30	2014-12-16	Abbvie Inc.	Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos
ES2409844T3 (es) *	2006-01-30	2013-06-28	Grifols Therapeutics Inc.	Metodo para el tratamiento y la profilaxis de enfermedades relacionadas con la deposicion de amiloide utilizando IgM
US7932261B2 (en) *	2006-02-06	2011-04-26	Janssen Pharmaceutica Nv	Macrocycle derivatives useful as inhibitors of β-secretase (BACE)
WO2007092854A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007092846A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
TW200808751A (en) *	2006-04-13	2008-02-16	Astrazeneca Ab	New compounds
US8784810B2 (en) *	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
DK1849762T3 (da) *	2006-04-21	2009-10-12	Cellzome Ltd	Substituerede biphenylcarboxylsyrer og derivater deraf
EP2687223B1 (en)	2006-05-30	2017-07-12	Mayo Foundation For Medical Education And Research	Detecting and treating dementia
JP5123936B2 (ja) *	2006-05-30	2013-01-23	メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ	認知症の検出および治療
TW200815349A (en)	2006-06-22	2008-04-01	Astrazeneca Ab	New compounds
CA2660321A1 (en) *	2006-08-10	2008-02-21	The Board Of Trustees Of The Leland Stanford Junior University	Differential labeling of cells
AU2007357451B2 (en)	2006-10-12	2012-11-15	Bhi Limited Partnership.	Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
US8575120B2 (en)	2007-03-13	2013-11-05	The Children's Hospital Of Philadelphia	Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
US8003097B2 (en) *	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
JP2011526240A (ja) *	2007-04-18	2011-10-06	ヤンセンアルツハイマーイミュノセラピー	脳アミロイド血管症の予防および治療
AU2008254905A1 (en) *	2007-05-15	2008-11-27	Helicon Therapeutics, Inc.	Methods of treating cognitive disorders by inhibition of Gpr12
WO2009007300A2 (en)	2007-07-06	2009-01-15	Boehringer Ingelheim International Gmbh	Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
ES2498040T3 (es)	2007-07-27	2014-09-24	Janssen Alzheimer Immunotherapy	Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JP5049713B2 (ja) *	2007-09-14	2012-10-17	株式会社コナミデジタルエンタテインメント	ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
JO3076B1 (ar) *	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EA017616B1 (ru) *	2007-10-17	2013-01-30	Янссен Фармацевтика, Н.В.	Дифенилкарбоновые кислоты и их производные
BRPI0817789A2 (pt) *	2007-10-19	2015-03-24	Janssen Pharmaceutica Nv	Intermediários de moduladores de gama secretase (gsm)
BRPI0817837A2 (pt) *	2007-10-19	2015-04-07	Janssen Pharmaceutica Nv	Moduladores de gama-secretase ligados a amida
KR20100090265A (ko) *	2007-10-19	2010-08-13	얀센 파마슈티카 엔.브이.	γ-세크레타아제의 아미드 결합된 조절제
ES2401833T3 (es)	2007-10-19	2013-04-24	Janssen Pharmaceutica, N.V.	Moduladores enlazados de carbono de y-secretasa
ATE543799T1 (de) *	2007-10-19	2012-02-15	Janssen Pharmaceutica Nv	Piperidinyl- und piperazinylmodulatoren von g- sekretase
US8420088B2 (en)	2008-01-28	2013-04-16	Novartis Ag	Methods and compositions using FGF23 fusion polypeptides
CN101925578B (zh) *	2008-01-28	2012-11-28	詹森药业有限公司	可用作β-分泌酶(BACE)抑制剂的6-取代-硫代-2-氨基-喹啉衍生物
TW200936156A (en)	2008-01-28	2009-09-01	Novartis Ag	Methods and compositions using Klotho-FGF fusion polypeptides
RU2010136050A (ru) *	2008-01-29	2012-03-10	Янссен Фармацевтика Нв (Be)	2-аминохинолиновые производные для использования в качестве ингибиторов секретазы (васе)
EP2257643B1 (en)	2008-02-19	2015-04-08	The Children's Hospital Of Philadelphia	Identification of pediatric onset inflammatory bowel disease loci and methods of use thereof for the diagnosis and treatment of the same
AU2009246134B2 (en)	2008-05-16	2016-03-03	The Children's Hospital Of Philadelphia	Genetic alterations on chromosomes 21q, 6q and 15q and methods of use thereof for the diagnosis and treatment of type I diabetes
WO2009155133A1 (en) *	2008-06-20	2009-12-23	Centocor Ortho Biotech Inc.	Method for testing efficacy of treatment of neurologic disorders
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
US20100125087A1 (en) *	2008-11-14	2010-05-20	Astrazeneca Ab	New compounds 575
US20100125081A1 (en) *	2008-11-14	2010-05-20	Astrazeneca Ab	New compounds 574
TW201020244A (en) *	2008-11-14	2010-06-01	Astrazeneca Ab	New compounds
US20110023152A1 (en) *	2008-12-04	2011-01-27	Sigma-Aldrich Co.	Genome editing of cognition related genes in animals
US8008539B1 (en)	2009-03-19	2011-08-30	University Of South Florida	Generation of transgenic human soluble amyloid precursor protein alpha expressing mice
WO2011057214A2 (en)	2009-11-09	2011-05-12	Neurogenetic Pharmaceuticals, Inc.	Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor
MX336196B (es)	2010-04-15	2016-01-11	Abbvie Inc	Proteinas de union a amiloide beta.
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
ES2705027T3 (es)	2010-08-19	2019-03-21	Buck Institute For Age Res	Métodos de tratamiento del deterioro cognitivo leve (DCL) y trastornos relacionados
WO2013027191A1 (en)	2011-08-25	2013-02-28	Novartis Ag	Methods and compositions using fgf23 fusion polypeptides
JP5605718B2 (ja) *	2012-01-23	2014-10-15	独立行政法人理化学研究所	アルツハイマー病モデル動物およびその用途
CN104270945B (zh)	2012-03-19	2017-03-29	巴克老龄化研究所	App特异性bace抑制剂(asbi)及其用途
CN104995176B (zh)	2013-02-12	2019-02-22	巴克老龄化研究所	调节bace所介导的app加工的乙内酰脲
WO2016077078A1 (en)	2014-10-29	2016-05-19	The Children's Hospital Of Philadelphia	Diagnosis and treatment of genetic alterations associated with eosinophilic esophagitis
EA201791238A1 (ru)	2014-12-04	2018-02-28	Новартис Аг	Способы и композиции, в которых используются варианты полипептидов klotho
WO2016198627A1 (en) *	2015-06-12	2016-12-15	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical composition for the treatment of alzheimer's disease
AU2016313504A1 (en)	2015-08-21	2018-03-08	The Children's Hospital Of Philadelphia	Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
WO2017035529A1 (en)	2015-08-27	2017-03-02	Nantneuro, Llc	Compositions for app-selective bace inhibition and uses therfor
CA3024067C (en)	2016-05-12	2024-04-09	Buck Institute For Research On Aging	Compounds to promote normal processing of app
AU2021402944A1 (en) *	2020-12-16	2023-07-13	The Jackson Laboratory	A genetically modified immunodeficient mouse expressing human or humanized app and mutated human psen1

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873191A (en) *	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
AU3056289A (en) *	1988-01-13	1989-08-11	Mclean Hospital Corporation, The	Genetic constructs containing the alzheimer brain amyloid gene
EP0451700A1 (en) *	1990-04-10	1991-10-16	Miles Inc.	Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
DE69133372T2 (de) *	1990-06-15	2005-02-24	Scios Inc., Sunnyvale	Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
EP0550675A1 (en) *	1990-09-28	1993-07-14	Cephalon, Inc.	Transgenic animals with alzheimer's amyloid precursor gene
DE971033T1 (de) *	1991-01-21	2001-05-03	Imperial College Of Science, Technology & Medicine	Prüfung und Modell für Alzheimers-Krankheit
US5672805A (en) *	1991-07-18	1997-09-30	The Regents Of The University Of California	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
DE69233109T2 (de) *	1992-01-07	2004-05-19	Elan Pharmaceuticals, Inc., San Francisco	Transgene tiermodelle fur alzheimer-krankheit
US5604102A (en) *	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
US5455169A (en) *	1992-06-04	1995-10-03	Alzheimer's Institute Of America, Inc.	Nucleic acids for diagnosing and modeling Alzheimer's disease
DE1001019T1 (de) *	1993-10-27	2001-01-11	Athena Neurosciences Inc	Transgene Tiere, die APP Allele mit der schwedischen Mutation beherbergen
JPH07132033A (ja) *	1993-11-12	1995-05-23	Hoechst Japan Ltd	アルツハイマー病モデルトランスジェニック動物
US5877399A (en) *	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
JPH09511388A (ja) *	1994-01-27	1997-11-18	リージェンツオブザユニバーシティーオブミネソタ	進行性神経疾患を持つヒト以外のトランスジェニック哺乳類

1996
- 1996-06-17 US US08/664,872 patent/US5877399A/en not_active Expired - Lifetime
1997
- 1997-06-17 JP JP10503108A patent/JP2000513929A/ja active Pending
- 1997-06-17 CA CA2257852A patent/CA2257852C/en not_active Expired - Lifetime
- 1997-06-17 WO PCT/US1997/010052 patent/WO1997048792A1/en not_active Application Discontinuation
- 1997-06-17 EP EP97931096A patent/EP0904349A4/en not_active Withdrawn
- 1997-06-17 AU AU34818/97A patent/AU3481897A/en not_active Abandoned
1999
- 1999-03-02 US US09/260,897 patent/US6509515B2/en not_active Expired - Fee Related
2002
- 2002-10-15 US US10/271,314 patent/US20030229907A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US5877399A (en)	1999-03-02
WO1997048792A1 (en)	1997-12-24
JP2000513929A (ja)	2000-10-24
CA2257852A1 (en)	1997-12-24
EP0904349A1 (en)	1999-03-31
US20020019992A1 (en)	2002-02-14
US6509515B2 (en)	2003-01-21
EP0904349A4 (en)	2002-09-25
AU3481897A (en)	1998-01-07
US20030229907A1 (en)	2003-12-11

Legal Events

Date	Code	Title	Description
2002-06-12	EEER	Examination request
2017-08-21	MKEX	Expiry	Effective date: 20170619

Publication	Publication Date	Title
CA2257852C (en)	2010-02-23	Transgenic non-human mammals with progressive neurologic disease
EP0742831B1 (en)	2004-09-29	Transgenic non-human mammals with progressive neurologic disease
WO1997048792A9 (en)	1998-04-02	Transgenic non-human mammals with progressive neurologic disease
AU671093B2 (en)	1996-08-15	Transgenic animal models for alzheimer's disease
US6717031B2 (en)	2004-04-06	Method for selecting a transgenic mouse model of alzheimer's disease
US7309812B2 (en)	2007-12-18	Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses
JP2001517065A (ja)	2001-10-02	トランスジェニック動物モデルを用いてアルツハイマー病治療薬を同定する方法
JP5070236B2 (ja)	2012-11-07	神経変性性障害のトランスジェニック動物モデル
WO1996040896A1 (en)	1996-12-19	Method for identifying alzheimer's disease therapeutics using transgenic animal models
US7767879B2 (en)	2010-08-03	Transgenic animal model of neurodegenerative disorders
CA2814737C (en)	2018-09-11	Use of an a.beta.42 peptide to reduce a cognitive deficit in a subject
Wadsworth et al.	1998	Transgenic mouse expressing APP 770